A Randomized Open-Label 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
-
- STATUS
- Not Recruiting
Summary
The purpose of this study is to determine the dose of the study drug INCB047986 that is safe and tolerable when given to subjects that have MDS resistant to, or unlikely to respond to Erthyropoiesis-Stimulating Agents (ESAs). Also to further study the selected dose(s) of the study drug INCB047986 that is safe and tolerable when given in combination with ESAs.
Description
The purpose of this study is to determine the dose of the study drug INCB047986 that is safe and tolerable when given to subjects that have MDS resistant to, or unlikely to respond to Erthyropoiesis-Stimulating Agents (ESAs). Also to further study the selected dose(s) of the study drug INCB047986 that is safe and tolerable when given in combination with ESAs.
Details
| Condition | myelodysplastic syndrome |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX4297 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.